[an error occurred while processing this directive] | [an error occurred while processing this directive]
Hypofractionated radiotherapy and tumor immunity — new concepts and new combination
Liu Sihan,Tian Ye,Zhang Daxin
Department of Oncology,First Affiliated Hospital,Harbin Medical University,Harbin 150001,China (Liu SH,Zhang DX);Department of Radiotherapy&Oncology,Second Affiliated Hospital of Soochow University,Suzhou 215004,China (Tian Y)
Abstract Modern immunology has established that tumor immune escape is associated with hidden or missing tumor-specific antigens and tumor-associated antigens, as well as immune suppressors that are released from tumor cells to inhibit the immune cytotoxicity and antigen-presenting cells (APCs). The changes in tumor microenvironment have an impact on tumor immunity and treatment outcomes. The immune effects finally depend on activation and inhibition of T cell receptors and other co-regulated receptors (CD28, CD80/CD86, and CTLA-4) in spite of the existence of APCs and cytotoxic T lymphocytes in tumor microenvironment. Recent studies have revealed that radiotherapy induced not only DNA damage but also immunogenesis in tumor cells. Both conventionally fractionated radiotherapy and hypofractionated radiotherapy can induce immunogenesis in tumor cells. Immunogenic regulation makes many tumor antigens expressed in cells exposed to irradiation, which induces immune recognition and cytotoxicity;cell content (DNA, HMGB1, etc.) released from dead immunogenic cells can trigger immune effects and in situ tumor vaccination, which further induce an abscopal effect of radiotherapy. A lot of anti-tumor immunotherapy fails to achieve satisfactory treatment outcomes. Therefore, how to combine radiotherapy, especially stereotactic body radiotherapy, with anti-tumor immunotherapy has recently become a new challenge for researchers.
Liu Sihan,Tian Ye,Zhang Daxin. Hypofractionated radiotherapy and tumor immunity — new concepts and new combination[J]. Chinese Journal of Radiation Oncology, 2016, 25(7): 777-781.
Liu Sihan,Tian Ye,Zhang Daxin. Hypofractionated radiotherapy and tumor immunity — new concepts and new combination[J]. Chinese Journal of Radiation Oncology, 2016, 25(7): 777-781.
[1]Blades RA,Keating PJ,McWilliam LJ,et al. Loss of HLA class I expression in prostate cancer:implications for immunotherapy[J].Urology,1995,46(5):681-687.DOI:10.1016/S0090-4295(99)80301-X [2]Ben-Shoshan J,Maysel-Auslender S,Mor A,et al. Hypoxia controls CD4+CD25+ regulatory T-cell homeostasis via hypoxia-inducible factor-1alpha[J].Eur J Immunol,2008,38(9):2412-2418.DOI:10.1002/eji.200838318 [3]Wunderlich R,Frischholz B,Roedel F.Ionising radiation with single doses up to clinical relevant 2 Gy does not influence viability and phagocytosis capability of single activated macrophages of radiosensitive BALB/c mice[Z].Strahlenther Onkol,2013,189[Abstractband zur 19.Jahrestagung der Deutschen Gesellschaft für Radioonkologie (DEGRO)]:122 [4]Chakraborty M,Abrams SI,Coleman CN,et al. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing[J].Cancer Res,2004,64(12):4328-4337.DOI:10.1158/0008-5472.CAN-04-0073 [5]Reits EA,Hodge JW,Herberts CA,et al. Radiation modulates the peptide repertoire,enhances MHC class I expression,and induces successful antitumor immunotherapy[J].J Exp Med 2006,203(5):1259-1271.DOI:10.1084/jem.20052494 [6]Lee YJ,Auh SL,Wang YG,et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells:changing strategies for cancer treatment[J].Blood,2009,114(3):589-595.DOI:10.1182/blood-2009-02-206870 [7]Matsumura S,Wang BM,Kawashima N,et al. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells[J].J Immunol,2008,181(5):3099-3107.DOI:10.4049/jimmunol.181.5.3099 [8]Kumari A,Cacan E,Greer S,et al. Turning T cells on:epigenetically enhanced expression of effector T-cell costimulatory molecules on irradiated human tumor cells[J].J Immunother Cancer,2013,1:17.DOI:10.1186/2051-1426-1-17 [9]Beyer C,Stearns NA,Giessl A,et al. The extracellular release of DNA and HMGB1 from Jurkat T cells during in vitro necrotic cell death[J].Innate Immun,2012,18(5):727-737.DOI:10.1177/1753425912437981 [10]Krysko DV,Garg AD,Kaczmarek A,et al. Immunogenic cell death and DAMPs in cancer therapy[J].Nat Rev Cancer,2012,12(12):860-875.DOI:10.1038/nrc3380 [11]Apetoh L,Tesniere A,Ghiringhelli F,et al. Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies[J].Cancer Res,2008,68(11):4026-4030.DOI:10.1158/0008-5472.CAN-08-0427 [12]Vabulas RM,Braedel S,Hilf N,et al. The endoplasmic reticulum-resident heat shock protein Gp96 activates dendritic cells via the Toll-like receptor 2/4 pathway[J].J Biol Chem,2002,277(23):20847-20853 [13]Gregory CD,Pound JD.Microenvironmental influences of apoptosis in vivo and in vitro[J].Apoptosis,2010,15(9):1029-1049.DOI:10.1007/s10495-010-0485-9 [14]Ferguson TA,Choi J,Green DR.Armed response:how dying cells influence T-Cell functions[J].Immunol Rev,2011,241(1):77-88.DOI:10.1111/j.1600-065X.2011.01006.x [15]Gajewski TF,Fuertes M,Spaapen R,et al. Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment[J].Curr Opin Immunol,2011,23(2):286-292.DOI:10.1016/j.coi.2010.11.013 [16]Demaria S,Ng B,Devitt ML,et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated[J].Int J Radiat Oncol Biol Phys,2004,58(3):862-870.DOI:10.1016/j.ijrobp.2003.09.012 [17]Takeshima T,Chamoto K,Wakita D,et al. Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL:its potentiation by combination with Th1 cell therapy[J].Cancer Res,2010,70(7):2697-2706.DOI:10.1158/0008-5472.CAN-09-2982 [18]Teitz-Tennenbaum S,Li Q,Davis MA,et al. Radiotherapy combined with intratumoral dendritic cell vaccination enhances the therapeutic efficacy of adoptive T-cell transfer[J].J Immunother,2009,32(6):602-612.DOI:10.1097/CJI.0b013e3181a95165 [19]Chi KH,Liu SJ,Li CP,et al. Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma[J].J Immunother,2005,28(2):129-135 [20]Shibamoto Y,Okamoto M,Kobayashi M,et al. Immune-maximizing (IMAX) therapy for cancer:combination of dendritic cell vaccine and intensity-modulated radiation[J].Mol Clin Oncol,2013,1(4):649-654.DOI:10.3892/mco.2013.108 [21]Mason KA,Ariga H,Neal R,et al. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy[J].Clin Cancer Res,2005,11(1):361-369 [22]Hart JP,Carpenter J,Patel NB,et al. CpG Oligodeoxynucleotides (CpG ODN) immunotherapy enhances tumor radioresponse:systemic effects and mechanisms[J].Int J Radiat Oncol Biol Phys,2008,72(1):S168.DOI:10.1016/j.ijrobp.2008.06.523 [23]Brody JD,Ai WZ,Czerwinski DK,et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression:a phase Ⅰ/Ⅱ study[J].J Clin Oncol,2010,28(28),4324-4332.DOI:10.1200/JCO.2010.28.9793 [24]Kim, Y. H., Gratzinger, D., Harrison, C., et al. In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 ago-nist combined with radiation:a phase 1/2 study. Blood, 2012, 119:355-363 [25]Pardoll DM.The blockade of immune checkpoints in cancer immunotherapy[J].NatRev Cancer,2012,12(4):252-264.DOI:10.1038/nrc3239 [26]Stephen Hodi F,O′ Day SJ,McDermott DF,et al. Improved survival with ipilimumab in patients with metastatic melanoma[J].N Engl J Med,2010,363(8):711-723.DOI:10.1056/NEJMoa1003466 [27]Demaria S,Kawashima N,Yang AM,et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer[J].Clin Cancer Res,2005,11(2 pt 1):728-734 [28]Kwon ED,Drake CG,Scher HI,et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043):a multicentre,randomised,double-blind,phase 3 trial[J].Lancet Oncol,2014,15(7):700-712. DOI:http://dx.doi.org/10.1016/S1470-2045(14)70189-5 [29]Brahmer JR,Tykodi SS,Chow LQM,et al. Safety and activity of anti–PDL1 antibody in patients with advanced cancer[J].N Engl J Med,2012,366(26):2455-2465.DOI:10.1056/NEJMoa1200694 [30]Tabernero J,Powderly JD,Hamid O,et al. Clinical activity,safety,and biomarkers with MPDL32801A,an engineered anti-PDL1 antibody in patients with locally advanced or metastatic malignant melanoma[J].J Clin Oncol,2012,31(15_Suppl):3022 [31]Zeng J,See AP,Phallen J,et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas[J].Int J Radiat Oncol Biol Phys,2013 86(2):343-349.DOI:10.1016/j.ijrobp.2012.12.025 [32]Deng LF,Liang H,Burnette B,et al. Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice[J].J Clin Invest,2014,124(2):687-695.DOI:10.1172/JCI67313.
2016, Vol. 25 
